Program
luvesilocin
Its studies are mostly in Adjustment Disorders · Generalized Anxiety Disorder · Depression, Postpartum · Breast Feeding, led by Reunion Neuroscience.
Furthest: phase 2, since Mar 26, 20244 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Reunion Neuroscience | 42 open or running | phase 2since Mar 26, 2024 | Mar 26, 2024 | Apr 2027phase 2 · NCT07002034 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 26, 2024First study: phase 2 study in Depression, PostpartumFirst studyNCT06342310 · 84 enrolled · United States
- Oct 14, 2024Phase 1 study in Breast FeedingNCT06659263 · 14 enrolled · United States
- May 23, 2025Phase 2 study in Adjustment DisordersNCT07002034 · 100 planned · United States
- Mar 18, 2026Phase 2 study in Generalized Anxiety DisorderNCT07489651 · 160 planned · United States
Ahead
- Apr 2027Primary completion: phase 2 study in Adjustment DisordersNCT07002034
- Jul 2027Primary completion: phase 2 study in Generalized Anxiety DisorderNCT07489651
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07489651Generalized Anxiety Disorder · United States | 2 | Recruiting | Jul 2027 | 160 |
| NCT07002034Adjustment Disorders · United States | 2 | Recruiting | Apr 2027 | 100 |
| NCT06659263Breast Feeding · United States | 1 | Completed | May 28, 2025 | 14 |
| NCT06342310Depression, Postpartum · United States | 2 | Completed | May 22, 2025 | 84 |
How it is read
Names in the registry
- “RE104 for Injection”, 4 entries
Conditions, from the studies’ own filings
- Adjustment Disorders, 1 study
- Generalized Anxiety Disorder, 1 study
- Depression, Postpartum, 1 study
- Breast Feeding, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.